Nice one, Balance, attacking someone whom you know no longer has the ability to reply here.
Do enjoy your temporary time in the sun.
Printable View
Nice one, Balance, attacking someone whom you know no longer has the ability to reply here.
Do enjoy your temporary time in the sun.
I'm sure it has been said before - 1071 pages dedicated to a company that has gone nowhere
EX 1H18 Report: In addition, Pacific Edge is continuing to work through the process required to gain inclusion in the LCD from the CMS. Once this is received, it will enable consistent and timely reimbursement for Medicare patients, on normal CMS payment terms. The inclusion into the LCD and the commensurate pricing negotiation will provide the catalyst for Pacific Edge to negotiate agreements with other private payers which view the CMS pricing as a benchmark, providing further certainty on price and payment terms for Pacific Edge.
Seems like a heavily implied confirmation to me. ( maybe it really is on its way and it kills them not to be able to come out and just say so? )
I have not found this sort of confirmatory statement in the last 4 reports...
Because I am a layman I do not see PEB's differentiation from the rest of the market, BTA TRAK® + NMP-22 BladderChek® + The UroVysion® are all bladder cancer diagnostic and monitoring products that are already approved by the FDA and granted LCD ( which PEB has been progressing through for the last 4 years ) - PEB said they were ahead of the competition though... am i missing something?
PEB has the more accurate test (significantly) but not having the LCD is a massive handycap to the certainty around reimbursement/flows.
The "Once this is received" is better terminology than "If this is received" which is why they have used it. I believe they will get LCD but very late in the piece, and long after Kaiser is ticked off with an agreement. (IMHO)
I agree with Balance that PEB should have scoped more heavily the reality of the US health system pertaining to the penetration of new products, instead of learning on the fly. As healthcare is so volatile at the moment in the US, PEB may have no choice but to learn new things on the fly.
In relation to some of the conspiracy theories around the spending habits of DD, I trust that he is generally responsible along these lines and only makes US trips when he has to. It's reasonable to assume the 'transformational' customers or other big groups would want to see DD directly (even in preference to a high quality Skype) for hand-shakes, and I would expect DD to incur the highest travel costs. Premium economy can be justified in my view and mid range accommodation. Bringing family along would be unacceptable. Is there anything public on the PEB travel policy for staff?
I think in older annual reports (I havent seen them do this recently) they had a line for Conference/Travel expenses, might have been ~$2M back in 2015? I could be imagining things, someone diligent might find this?